Treatment and outcomes of chronic coronary syndromes: the EORP EURECA imaging registry

: Liga, Riccardo; Gimelli, Alessia; Podlesnikar, Tomaz; Cvijic, Marta; Pontone, Gianluca; Miglioranza, Marcelo Haertel; Guaricci, Andrea Igoren; Seitun, Sara; Clemente, Alberto; Sumin, Alexey; Vitola, Joao; Saraste, Antti; Paunonen, Christian; Sia, Ching-Hui; Paleev, Filipp; Sade, Leyla Elif; Zamorano, Jose Luis; Maroz-Vadalazhskaya, Natallia; Sredojevic, Mirjana; Anagnostopoulos, Constantinos; Macedo, Filipe; Knuuti, Juhani; Edvardsen, Thor; Cosyns, Bernard; Petersen, Steffen E.; Magne, Julien; Laroche, Cecile; Popescu, Bogdan A.; Delgado, Victoria; Neglia, Danilo; EURECA Investigators

Publisher: Oxford University Press (OUP)

: 2025

: European Heart Journal

: ehaf594

: 46

: 39

: 3922

: 3927

: 0195-668X

: 1522-9645

DOI: https://doi.org/10.1093/eurheartj/ehaf594

: https://doi.org/10.1093/eurheartj/ehaf594

: 
Since the start of EORP, the following companies have supported the programme: Abbott Vascular (2011–2021), Amgen (2009–2018), AstraZeneca France (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific Corporation (2009–2012), Bristol-Myers Squibb and Pfizer (2011–2019), Daiichi Sankyo Europe (2011–2020), The Daiichi Sankyo Europe and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter (2014–2016), Menarini Group (2009–2012), Merck Sharp and Dohme France (2011–2014), Novartis Pharma (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), Servier (2009–2018), Vifor Pharma (2019–2022).